Das hat vermutlich auch mit gestiegener Aufmerksamkeit zu tun. Letzt Woche erschienen zwei Artikel zu Magenta:
www.businessinsider.com/...of-biotech-ma-2021-2?r=DE&IR=T
www.fool.com/investing/2021/02/27/...amp;utm_campaign=article
Dort geht es zwar nicht um das von HP auslizensierte Target, aber erhöhte Aufmerksamkeit kann sicher nicht schaden.
Gestern gab es dann aber noch ein Q4 Update seitens Magenta. Auch zu MGTA-117 gab es ein paar Updates. Noch dieses Jahr will man mit der Phase 1/2 erste Safety Daten generiert haben.
MGTA-117: Targeted Conditioning –
Magenta is developing a platform of novel antibody-drug conjugates (ADCs) for conditioning, a step in the transplant process that currently relies on the use of systemic chemotherapy agents and radiation. Magenta’s targeted conditioning programs are designed to selectively eliminate stem cells and/or immune cells from a patient prior to transplant or gene therapy, and to reduce or potentially eliminate the need for high dose or high intensity chemotherapy-based regimens.
MGTA-117, Magenta’s most advanced conditioning program, is a CD117-targeted antibody conjugated to amanitin and intended for use in patients undergoing transplant. MGTA-117 is designed to deplete hematopoietic stem and progenitor cells to clear space in the bone marrow prior to transplant in support of long-term engraftment and improved disease outcomes in patients. MGTA-117 has shown high selectivity, potent efficacy and tolerability in multiple preclinical studies.
Targeted Conditioning Current and Planned Activity:
- MGTA-117 IND Filing Anticipated Mid-2021. Magenta recently completed its GLP toxicology studies, its GMP manufacturing process and has finished its pre-Investigational New Drug (IND) communications with the FDA and expects to file an IND application in mid-2021. Upon acceptance of the IND by the FDA, Magenta plans to initiate a Phase 1/2 clinical trial evaluating MGTA-117 in patients with AML and MDS to generate initial safety and pharmacokinetic data in the fourth quarter of 2021. These initial data are expected to be directional for the Company’s dose escalation plans.
- Magenta continues to evaluate CD45-ADC preclinically in various transplant and autoimmune disease models.
Targeted Conditioning Recent and Upcoming Scientific Conference Presentations:
- Magenta provided updates on its MGTA-117 and CD45-ADC conditioning programs at the ASH Annual Meeting:
-- In preclinical animal models of human AML, MGTA-117 decreased tumor burden leading to increased median survival rates versus a multi-day standard-of-care regimen.
-- Preclinical data from a study of Magenta’s CD45-ADC conditioning program demonstrated the potential to achieve successful disease outcomes as a single agent in a fully mismatched allogeneic HSC transplant preclinical disease model.
- Magenta gave an oral presentation of MGTA-117 and presented a poster of CD45-ADC at the TCT Annual Meeting:
-- MGTA-117 was studied in multiple human leukemic xenograft preclinical models to mimic untreated and refractory AML. In preclinical models, MGTA-117 increased median survival versus a multi-day standard-of-care regimen using cytarabine.
-- Preclinical data demonstrated that conditioning with single agent CD45-ADC enabled complete chimerism in a full mismatch allogeneic HSC transplant model. Developing a broad targeting approach for safer patient conditioning prior to HSC transplant could bring the curative potential of allogeneic HSC transplant to more patients with both malignant and non-malignant disorders. Current conditioning regimens limit accessibility of this procedure due to toxicity.
-Magenta will also present data on its MGTA-117 conditioning program at the upcoming European Society for Blood and Marrow Transplantation (EBMT) annual meeting, to be held March 14-17, 2021.